RT Conference Proceedings
T1 Neoadjuvant nivolumab (NIVO) plus palbociclib (PALBO) plus anastrozole (ANA) for estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) primary breast cancer (BC): CheckMate 7A8
A1 Jerusalem, G.
A1 Prat, A.
A1 Salgado, R. F.
A1 Reinisch, M.
A1 Saura, C.
A1 Ruiz Borrego, M.
A1 Nikolinakos, P.
A1 Filian, J.
A1 Ades, F.
A1 Huang, N.
A1 Mazzei-Abba, A.
A1 Tolaney, S. M.
PB Elsevier
SN 0923-7534
YR 2022
FD 2022-05-05
LK http://hdl.handle.net/10668/21901
UL http://hdl.handle.net/10668/21901
LA en
DS RISalud
RD Apr 7, 2025